Natural Monoclonal Antibodies and Cancer

Author(s): Peter H. Vollmers , Stephanie Brandlein .

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 3 , Issue 2 , 2008

Become EABM
Become Reviewer

Abstract:

Immunity is responsible for recognition and elimination of infectious particles and for removal of cellular waste, modified self structures and transformed cells. Innate or natural immunity acts as a first line defense and is also the link to acquired immunity and memory. By using the human hybridoma technology, a series of monoclonal antibodies and several new tumor-specific targets could be identified. A striking phenomenon of immunity against malignant cells is that all so far isolated tumor-specific antibodies were germ-line coded natural IgM antibodies. And neither in animals nor in humans affinity-maturated tumor-specific IgG antibodies have been detected so far. These IgM´s preferentially bind to carbohydrate epitopes on post-transcriptionally modified surface receptors, which are recently patented and preferentially remove malignant cells by inducing apoptosis to avoid inflammatory processes. Our “biology-” or “function-driven” method represents a unique yet powerful approach compared to the typical approaches on screening compounds or antibodies against non-validated targets (mostly differentially expressed). Moreover, the approach creates a competitive patenting strategy of creating proprietary antibodies and validated targets at the same time, which has the potential of further streamlining the discovery of new cancer therapies.

Keywords: Natural IgM antibodies, cancer, autoimmunity, immune surveillance

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 3
ISSUE: 2
Year: 2008
Page: [84 - 87]
Pages: 4
DOI: 10.2174/157489208784638758
Price: $58

Article Metrics

PDF: 3